MEK-Inhibitors-Modulators-生命科学试剂-MedChemExpress.pdf

MEK Mitogen-activated protein kinase kinase; MAPKK; MAP2K PMEK (Mitogen-activated protein kinase kinase, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinases (MAPKs). The activated MAPK leads to the phosphorylation of downstream transcription factors that regulate various responses such as stress signaling, pathogen response, and hormone signaling./P PIn general, the MAPKKK phosphorylates a serine or threonine residue on a MAPKK, which sequentially activates a MAPK (ERK, p38 or JNK), the last protein in the cascade. Activation of the p38 MAPK occurs mainly through mitogen-activated protein kinase kinase 3 (MKK3) and MKK6 (sometimes MKK4). The JNK is regulated by two upstream MAP2Ks: MKK4 and MKK7. The highly homologous kinases, MEK1 and MEK2, act downstream of Ras and Raf to activate ERK mitogen-activated protein kinases./P www.MedChemE 1 MEK Inhibitors, Antagonists Activators Anemarsaponin B APS-2-79 Cat. No.: HY-N0811 Cat. No.: HY-100627 Anemarsaponin B is a steroidal saponin. APS-2-79 is a KSR-dependent MEK antagonist. Anemarsaponin B decreases the protein and mRNA APS-2-79 inhibits ATPbiotin binding to KSR2 within levels of iNOS and COX-2. Anemarsaponin B reduces the KSR2-MEK1 complexe with an IC50 of 120 nM. the expressions and productions of APS-2-79 makes the stabilization of the KSR pro-inflammatory cytokines, incl